Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. is a U.S.-based commercial-stage company that has shifted from agricultural trait development toward consumer products and selective monetization of intellectual property. Its current operating business centers on Zola coconut water products, while legacy wheat trait assets and the GoodWheat brand have been sold or exited. The company also has a history of licensing and royalty activity tied to wheat-based technologies, but it no longer expects future license or royalty income from its wheat intellectual property. Recent disclosures show a business in transition, with product sales, asset sales, and patent monetization playing a larger role than ongoing agricultural R&D commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCoconut water and related hydration products sold under the Zola brand.
GLA oil products sold through product channels, with sales ending at the close of 2024.
Sales of patents, pending applications, and related intangible assets from legacy agricultural technologies.
Residual wheat trait-related commercialization and licensing activity, now largely exited.
Products
Reported · share of revenue- Products99.3 %
- Royalty0.5 %
- License0.1 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Arcadia’s current customers are primarily third-party distributors and retailers that buy Zola coconut water and related beverage products for resale to end consumers. The company also sells GLA products through product channels, although that business has been winding down. Historically, Arcadia also served agricultural and food-industry counterparties through seed, grain, ingredient, and trait-licensing arrangements, but those activities have been materially reduced or exited. The customer base is therefore a mix of consumer-product channel partners today and legacy technology counterparties from its earlier agricultural business model.
Buy Zola coconut water for resale in grocery, convenience, and other beverage channels because the product is a branded hydration item with seasonal consumer demand.
Purchase GLA oil products through product sales channels, although this segment has diminished as GLA oil sales ceased at the end of 2024.
Buy or license patent portfolios and related rights, such as the March 2025 sale of reduced gluten and oxidative stability patents and the 2024 RS durum wheat trait sale.
Previously bought seed, grain, food ingredients, and trait rights tied to wheat technologies, but this segment is now largely exited.
Strategy
Arcadia’s strategy has shifted from agricultural trait development toward monetizing remaining assets while supporting the Zola beverage business. The company has exited GoodWheat and no longer expects future wheat-based royalty income, which suggests a deliberate reduction in legacy agricultural commercialization. It is also actively managing its portfolio through patent sales and other asset monetization, as shown by the 2025 transfer of reduced gluten and oxidative stability patents and the 2024 RS durum wheat trait sale. At the operating level, the company appears focused on maintaining product sales, managing seasonal beverage demand, and preserving liquidity while operating with a small cash base.
Zola is the remaining operating product line and the main source of recurring product revenue.
Asset sales provide non-recurring cash and reduce the burden of maintaining non-core technologies.
The company has already exited GoodWheat and no longer expects wheat royalty income, indicating a strategic pivot away from the old model.
Geography
2025The company is headquartered in the United States and its disclosures point to a primarily U.S.-centric operating footprint. Its current business depends on domestic consumer-product distribution for Zola and on U.S.-based counterparties for intellectual property transactions and legacy asset sales. No country-level revenue breakdown was disclosed in the provided excerpts, so the geographic mix cannot be quantified from the available material. Geography matters mainly through U.S. retail channel access, domestic logistics, and exposure to U.S. consumer demand and inventory cycles.
Share of the revenue the company reports by geography.
Risks
Arcadia faces execution and liquidity risk because its business has been reduced to a small set of product lines and asset monetization opportunities. Beverage sales are seasonal, with higher volumes in warmer quarters, which can create meaningful quarter-to-quarter volatility in revenue and inventory needs. The company also depends on third-party distributors and retailers, so shipment timing, chargebacks, returns, and freight costs can materially affect reported results. More broadly, it remains exposed to consumer demand shifts in coconut water, the risk that remaining intangible assets cannot be monetized at attractive values, and the possibility that limited cash resources constrain operations.
The company has a small cash balance and has relied on equity proceeds, product sales, and asset sales to fund operations.
Exposure: Corporate funding and operating continuity
The company has sold key patent portfolios and no longer expects future wheat royalty income, limiting future IP cash flows.
Exposure: Legacy technology assets
Sales volumes are highest in the second and third fiscal quarters, making results uneven across periods.
Exposure: Zola beverage revenue
Revenue is recognized on delivery and fluctuates with shipment timing, which can delay or accelerate reported sales.
Exposure: Product revenue recognition
Accounting
Judgemental itemsSales are recognized when control transfers to distributors and retailers, making delivery timing and deductions important to reported revenue.
Impact: Quarterly revenue volatility and net sales presentation
Management identifies inventory valuation as a critical estimate, and write-downs can affect gross margin and operating results.
Impact: Cost of revenues and margin volatility
Patent and technology sales can create non-recurring gains that inflate reported earnings relative to operating performance.
Impact: Non-operating income and comparability
Higher summer sales can distort quarter-to-quarter trends and working capital needs.
Impact: Revenue, inventory, and cash flow timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Precision BioSciences, Inc
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
Assembly Biosciences, Inc
ASMB · Pharmaceutical Preparations
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Vita Coco Company, Inc.
COCO · Beverages
Last updated: 24/09/2026